Physician profile
Marsha Stapleton
NPI 1497138887
$4,083.71
in general payments reported to CMS, 2019-2025
15 companies · $1,891 in 2025
The $1,891 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $231 · 2023: $663 · 2024: $1,180 · 2025: $1,891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,721 · Education: $12.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,720.94 |
| Education | $12.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $863.52 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $861.33 | 2023-2025 | Auvelity |
| Abbvie INC. | $777.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $573.68 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $350.99 | 2024-2025 | Azstarys |
| Lundbeck LLC | $251.21 | 2022-2025 | Rexulti, Brintellix |
| E.R. Squibb & Sons, L.L.C. | $102.91 | 2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $66.46 | 2022-2025 | Ingrezza |
| Axonics, INC. | $46.54 | 2024 | Axonics |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.96 | 2022-2024 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $33.42 | 2024 | Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $31.36 | 2024-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $29.08 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $29.08 | 2025 | Zurzuvae |
| Tris Pharma INC | $22.85 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.